Alcohols-buliding-blocks

Turkiewicz, Anna; Steliga, Teresa; Kluk, Dorota; Gminski, Zbigniew published an article in 2021, the title of the article was Biomonitoring Studies and Preventing the Formation of Biogenic H2S in the Wierzchowice Underground Gas Storage Facility.Electric Literature of 4719-04-4 And the article contains the following content:

The article discusses the results of biomonitoring research at the Underground Gas Storage (UGS). Hydrogen sulfide, as one of the products of microbiol. reaction and transformation, as well as a product of chem. reactions in rocks, is a subject of interest for global petroleum companies. The materials used in this research work were formation waters and stored natural gas. The biomonitoring of reservoir waters and cyclical analyses of the composition of gas stored at UGS Wierzchowice enabled the assessment of the microbiol. condition of the reservoir environment and individual storage wells in subsequent years of operation. Investigations of the formation water from individual wells of the UGS Wierzchowice showed the presence of sulfate reducing bacteria bacteria (SRB), such as Desulfovibrio and Desulfotomaculum genera and bacteria that oxidize sulfur compounds In the last cycles of UGS Wierzchowice, the content of hydrogen sulfide and sulfides in the reservoir waters ranged from 1.22 to 15.5 mg/dm3. The monitoring of natural gas received from UGS production wells and observation wells, which was carried out in terms of the determination of hydrogen sulfide and organic sulfur compounds, made it possible to observe changes in their content in natural gas in individual storage cycles. In the last cycles of UGS Wierzchowice, the content of hydrogen sulfide in natural gas from production wells ranged from 0.69 to 2.89 mg/dm3, and the content of organic sulfur compounds converted to elemental sulfur ranged from 0.055 to 0.130 mg Sel./Nm3. A higher hydrogen sulfide content was recorded in natural gas from observation wells in the range of 2.02-25.15 mg/Nm3. In order to explain the causes of hydrogen sulfide formation at UGS Wierzchowice, isotopic analyses were performed to determine the isotope composition of δ34SH2S, δ34SSO4, δ18OSO4 in natural gas samples (production and observation wells) and in the deep sample of reservoir water. The results of isotope tests in connection with microbiol. tests, chromatog. analyses of sulfur compounds in natural gas collected from UGS Wierzchowice and an anal. of the geol. structure of the Wierzchowice deposit allow us to conclude that the dominant processes responsible for the formation of hydrogen sulfide at UGS Wierzchowice are microbiol., consisting of microbial sulfate reduction (MSR). The presented tests allow for the control and maintenance of hydrogen sulfide at a low level in the natural gas received from the Wierzchowice Underground Gas Storage facility. The experimental process involved the reaction of 2,2′,2”-(1,3,5-Triazinane-1,3,5-triyl)triethanol(cas: 4719-04-4).Electric Literature of 4719-04-4

The Article related to biogenic hydrogen sulfide wierzchowice underground gas storage biomonitoring, Electrochemical, Radiational, and Thermal Energy Technology: Energy Handling, Transport, and Storage and other aspects.Electric Literature of 4719-04-4

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On July 2, 2020, Okuda, Yasuhiro; Imafuku, Kazuto; Tsuchida, Yoshiyuki; Seo, Tomoyo; Akashi, Haruo; Orita, Akihiro published an article.COA of Formula: C10H22S The title of the article was Process-Controlled Regiodivergent Copper-Catalyzed Azide-Alkyne Cycloadditions: Tailor-made Syntheses of 4- and 5-Bromotriazoles from Bromo(phosphoryl)ethyne. And the article contained the following:

We developed a regiodivergent syntheses of 4- and 5-bromo-substituted 1,2,3-triazoles in copper-catalyzed azide-alkyne cycloadditions (CuAACs) by taking advantage of bromo(phosphoryl)ethyne as a bromoethyne equivalent A one-shot dephosphorylative CuAAC afforded 4-bromotriazoles, which was transformed into a histone deacetylase 8 (HDAC8)-selective inhibitor, NCC-149. However, the direct CuAAC catalyzed by CuI/Cu(OAc)2 provided 5-bromo-4-phosphoryltriazoles. The consecutive nucleophilic substitution of the bromo group with thiols followed by MeOK-promoted dephosphorylation gave 5-thio-substituted triazoles. The experimental process involved the reaction of 1-Decanethiol(cas: 143-10-2).COA of Formula: C10H22S

The Article related to bromotriazole regiodivergent preparation copper catalyzed click cycloaddition bromophosphorylethyne, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.COA of Formula: C10H22S

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On March 17, 2016, Viet, Andrew Quoc; Wurtz, Nicholas R. published a patent.Recommanded Product: 72364-46-6 The title of the patent was Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase. And the patent contained the following:

The invention provides compounds of formula I as myeloperoxidase (MPO) and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments. Compounds of formula I wherein ring A is substituted Ph and (un)substituted 5-to 6-membered heteroaryl; X is CH and N; Y is substituted hydrocarbon linker and substituted hydrocarbon-heteroatom linker; R1 is CN, OH, C1-4 (halo)alkyl, etc. ; and stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs and solvates thereof, are claimed. Example compound II was prepared by thiolation of 7-chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine with 1-phenylethylthiol. The invention compounds were evaluated for their myeloperoxidase and/or eosinophil peroxidase inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value ranged from 0.001 μM to 0.01 μM. The experimental process involved the reaction of (2-Fluorophenyl)methanethiol(cas: 72364-46-6).Recommanded Product: 72364-46-6

The Article related to preparation thioether triazolopyridine triazolopyrimidine inhibitor myeloperoxidase eosinophil peroxidase, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Recommanded Product: 72364-46-6

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On March 15, 2018, Sato, Takahiro; Nagayama, Yukiho; Yoshino, Yasuhiro; Inoue, Tsutomu; Kato, Hiroshige; Amata, Junichiro; Inaba, Masato; Yamoto, Noriko; Taniguchi, Tetsuya published a patent.HPLC of Formula: 386704-04-7 The title of the patent was Preparation of heterocyclic compounds having erythropoietin-production acceleration activity. And the patent contained the following:

Disclosed are compounds I [X = oxygen atom, nitrogen atom, sulfur atom, etc.; R1-R3 = independently H or alkyl; R4 = H, alkyl or aryl-alkyl; R5 = alkyl, alkenyl, alkynyl, etc. (wherein alkyl, alkenyl and alkynyl are optionally substituted with halo, methoxy, trifluoromethoxy, etc.); or pharmaceutically acceptable salts thereof] and pharmaceutical composition Thus, compound II was prepared via reaction of 2,4-dimethylbenzyl alc. with methanesulfonyl chloride followed by in-situ treatment with [(7-benzyloxy-5-mercapto[1,2,4]triazolo[1,5-a]pyridine-8-carbonyl)amino]acetic acid tert-Bu ester and de-esterification. The invention compounds, e.g., II, promoted erythropoietin (EPO) production in Hep3B cells. Of note, compounds I are useful for the treatment of anemia. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).HPLC of Formula: 386704-04-7

The Article related to heterocycle preparation erythropoietin production promoter, antianemic agent triazolopyridine erythropoietin production acceleration, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.HPLC of Formula: 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On December 25, 2007, Xu, Hao; Han, Guozhi; Sha, Fei; Xu, Jian; Yao, Cheng published an article.Application of 2160-93-2 The title of the article was Synthesis of N-(tert-butyl)piperazine. And the article contained the following:

A method for the synthesis of the title compound is reported here. The synthetic sequence involved a condensation of tert-butylamine (i.e., 2-methyl-2-propanamine) with ethylene oxide, chlorination, cyclization, hydrogenation, debenzylation. The target product was characterized by 1H NMR and MS and its purity was also tested by GC. Exptl. result showed that the reactant in this synthesis route was easily available and it could be applied to industrial production (no data). The experimental process involved the reaction of 2,2′-(tert-Butylazanediyl)diethanol(cas: 2160-93-2).Application of 2160-93-2

The Article related to dimethylethyl piperazine preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Application of 2160-93-2

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On March 12, 2020, Becker, Christopher; Li, Xiaolin; Lu, Peichao; Rajapaksa, Naomi Samadara; Tully, David Charles; Wang, Xiaojing Michael; Zhao, Qian published a patent.Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol The title of the patent was Preparation of pyridopyrazinedione compounds as antiviral agents for treating particularly herpes viruses. And the patent contained the following:

The invention is related to the preparation of compounds I [Cy = (un)substituted Ph, pyridinyl, pyrimidinyl, or a 5-8 membered cycloalkyl; R1, R2 = independently H, C1-3 alkyl; or R1CR2 = 3-6 membered cycloalkyl ring; R3 = 0-2 optional substituents on the ring to which -L-W is directly attached; R4 = H, halo, C1-3 alkyl; R5 = H, halo, CN, C1-3 alkoxy, etc.; L = C1-C4 straight chain or branched alkylene linker, or L = C1-C4 straight chain or branched alkylene linker or a bond when W is an optionally substituted ring; W = H, OH, an optionally substituted ring selected from 3-6 membered cycloalkyl, Ph, 5-6-membered heterocyclyl containing one or two N, O or S heteroatoms as ring members, and 5-membered heteroaryl containing up to 4 heteroatoms selected from N, O and S as ring members that is optionally fused to Ph, etc.; Y = (CH2)0-2] their pharmaceutically acceptable salts, to pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses. Thus, II (m.p. = 186°) was prepared by reaction of Bu 1,6-dioxo-2,3,4,6-tetrahydro-1H-pyrido[1,2-a]pyrazine-7-carboxylate (preparation given) with [1-(cyclopropylsulfonyl)cyclopropyl]methyl Methanesulfonate (preparation given) in DMF in the presence of NaH, acidulation of III•Na, activation of the acid III with oxalyl chloride, amidation with 4-(aminomethyl)benzonitrile hydrochloride. The exemplified compounds of the invention were studied in an CMV polymerase, CMV-luciferase and HSV polymerase assays (some data given). The activity of I against human herpes viruses CMV HSV-1, VZV and EBV was evaluated [Ec50 values of 24(±7) nM, 32(±12), 20(±8) and 12(±), resp]. The experimental process involved the reaction of 1-[(Dibenzylamino)methyl]cyclopropanol(cas: 428855-17-8).Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol

The Article related to pyridopyrazinedione preparation herpes antiviral, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On July 11, 2019, Qian, Wenyuan; Yang, Chundao; Xu, Guanghai; Li, Jie; Li, Jian; Chen, Shuhui published a patent.SDS of cas: 386704-04-7 The title of the patent was Preparation of isoindolinone and derivatives thereof as CSF-1R inhibitors. And the patent contained the following:

The present invention relates to a type of isoindolinone derivatives and use thereof in the preparation of a medicament for treating diseases associated with a novel colony stimulating factor 1 receptor (CSF-1R) inhibitor. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).SDS of cas: 386704-04-7

The Article related to isoindolinone preparation colony stimulating factor receptor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.SDS of cas: 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On November 29, 2018, Li, Liansheng; Feng, Jun; Wu, Tao; Liu, Yuan; Wang, Yi; Ren, Pingda; Liu, Yi published a patent.SDS of cas: 1620510-51-1 The title of the patent was Preparation of substituted quinazolines as covalent inhibitors of KRAS. And the patent contained the following:

The title compounds I [G1 and G2 = (independently) N or CH; L1 = a bond or NR6; L2 = a bond or alkylene; L3 = a bond, O, NR6, S, S(O) or SO2; R1 = unsubstituted naphthyl or optionally substituted quinolinyl when at least one of R31, R32, R41 and R42 is not H; or R1 = II (A1-A4 = (independently) C or N; X = O, S, N, etc.;Y = O, S, N, etc.; Z = O, S, N, etc.; one of R11-R14 is a covalent bond to the carbon attached to R1, and the other of R11-R14 = (independently) H, NH2, CN, etc.; R21-R23 = (independently) H, NH2, CN, etc.; R31 and R32 = (independently) H, OH, NH2, etc.; R41 and R42 = (independently) H, OH, NH2, etc.; R5 = NH2, CN, OH, etc.; R6 = (independently) H or alkyl; m and n = (independently) 1-3; and E = an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS, HRAS or NRAS G12C mutant protein)] or pharmaceutically acceptable salts, isotopic forms, stereoisomers or prodrugs thereof, having activity as inhibitors of G12C mutant KRAS protein, were prepared E.g., a multi-step synthesis of (2R,5S)-III, starting from 2-amino-4-bromo-3-fluorobenzoic acid, was described. Representative compounds I were tested and found to covalently bind to (or modify) KRAS G12C after a ten minute incubation period (data given). Pharmaceutical compositions comprising compounds I, and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, were also provided. The experimental process involved the reaction of (R)-(4-Methylmorpholin-3-yl)methanol(cas: 1620510-51-1).SDS of cas: 1620510-51-1

The Article related to quinazoline preparation g12c mutant kras inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.SDS of cas: 1620510-51-1

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On March 30, 2021, Guo, Hongli; Chen, Tao; Zhou, Feng; Gao, Daxin; Chen, Dawei published a patent.Reference of (R)-(4-Methylmorpholin-3-yl)methanol The title of the patent was Preparation of quinazoline-based compounds as KRAS G12C inhibitor for treatment and/or alleviation of KRAS G12C-related diseases. And the patent contained the following:

The present invention relates to preparation of quinazoline-based compounds as KRAS G12C inhibitor for treatment and/or alleviation of KRAS G12C-related diseases. In particular, the quinazoline-based compound I (wherein, α and β bonds are single bonds or double bonds, resp.; X = N or CR2; when the β bond is a single bond, Y = C(O) and Z = NR3; when the β bond is a double bond, Y and Z are independently N or CR2; when the α bond is a single bond, W = N and V = CH2 or C(O); when the a bond is a double bond, W = C and V = CR4 or N; U and M are each independently N, C or CH; ring A = Ph, 3-8 membered cycloalkyl, 5-6 membered heteroaryl or 4-8 membered heterocycloalkyl group; the A ring is unsubstituted or optionally substituted). Further, (ring B = 5-10 membered heterocycloalkyl; the B ring is unsubstituted or optionally substituted; R = C6-10 aryl, 5-10 membered heteroaryl or 9-14 membered fused heterocycloalkyl group; said R is unsubstituted or optionally substituted; R1 = C2-4 alkenyl, C2-4 alkynyl or partially unsaturated C4-6 cycloalkyl; said R1 is unsubstituted or optionally substituted; R2 = H, hydroxyl, halogen, cyano, amino etc.; R3 = C3-8 cycloalkyl, 3-8 membered heterocycloalkyl, C6-10 aryl, 5-10 heteroaryl, C3-8 cycloalkyl-C1-4 alkyl etc.; R4 = H, hydroxyl, halogen, C2-6 alkenyl, C2-6 alkynyl, cyano, amino etc.), its isomers, stable isotope derivatives or pharmaceutically acceptable salts were prepared The inventive compound and its composition disclosed can effectively treat diseases related to KRAS G12C, such as cancer. The experimental process involved the reaction of (R)-(4-Methylmorpholin-3-yl)methanol(cas: 1620510-51-1).Reference of (R)-(4-Methylmorpholin-3-yl)methanol

The Article related to quinazoline compound preparation kras g12c inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Reference of (R)-(4-Methylmorpholin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On February 11, 2016, Claremon, David A.; Dong, Chengguo; Fan, Yi; Leftheris, Katerina; Lotesta, Stephen D.; Singh, Suresh B.; Tice, Colin M.; Zhao, Wei; Zheng, Yajun; Zhuang, Linghang published a patent.Application of 386704-04-7 The title of the patent was Preparation of piperazine derivatives as liver X receptor modulators. And the patent contained the following:

Provided are novel compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver X receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver X receptor. Also provided are the compounds of formula I and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, Alzheimer’s disease, dermatitis, dyslipidemia, cancer and other diseases or disorders. Title compounds I [Q = alkyl-OC(O), heteroaryl, aryl-alkyl-OC(O), etc.; R1 = alkyl, cycloalkyl, aryl-alkyl, etc.; R2 = H, halo, cyano, etc.; R3 = alkyl, halo-alkyl, cycloalkyl, etc.; R4 = H or alkyl], and their pharmaceutically acceptable salts, are prepared Thus, e.g., II was prepared by reaction of (R)-tert-Bu 2-isopropylpiperazine-1-carboxylate with [3-(methylsulfonyl)phenyl]boronic acid. Compounds of the invention were evaluated for their LXr α/β binding ad agonist activity, e.g., II showed Ki value of 1690 nM and 157 nM on LXRα and LXRβ, resp. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Application of 386704-04-7

The Article related to piperazine derivative preparation liver receptor lxr modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Application of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts